{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,3,31]],"date-time":"2022-03-31T00:12:40Z","timestamp":1648685560600},"reference-count":39,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2001,12,1]],"date-time":"2001-12-01T00:00:00Z","timestamp":1007164800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Best Practice & Research Clinical Obstetrics & Gynaecology"],"published-print":{"date-parts":[[2001,12]]},"DOI":"10.1053\/beog.2001.0243","type":"journal-article","created":{"date-parts":[[2002,9,19]],"date-time":"2002-09-19T09:54:50Z","timestamp":1032429290000},"page":"999-1011","source":"Crossref","is-referenced-by-count":1,"title":["Drugs for obstetric conditions"],"prefix":"10.1053","volume":"15","author":[{"given":"Michael John","family":"Peek","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1053\/beog.2001.0243_RF1","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1016\/S0002-9378(00)70324-3","article-title":"Maternal mortality: confidential enquiries into maternal deaths in the United Kingdom","volume":"182","author":"De Swiet","year":"2000","journal-title":"American Journal of Obstetrics & Gynecology"},{"key":"10.1053\/beog.2001.0243_RF2","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1056\/NEJM200101043440107","article-title":"Drug Therapy: misoprostol and pregnancy","volume":"344","author":"Goldberg","year":"2001","journal-title":"New England Journal of Medicine"},{"key":"10.1053\/beog.2001.0243_RF3","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1016\/S0140-6736(94)92406-6","article-title":"Cervical priming with prostaglandin E1 analogues, misoprostol and gemeprost","volume":"343","author":"el Refaey","year":"1994","journal-title":"Lancet"},{"key":"10.1053\/beog.2001.0243_RF4","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1016\/S0029-7844(98)00281-6","article-title":"Randomized trial to determine optimal dose of vaginal misoprostol for preabortion cervical priming","volume":"92","author":"Sing","year":"1998","journal-title":"Obstetrics & Gynecology"},{"key":"10.1053\/beog.2001.0243_RF5","doi-asserted-by":"crossref","first-page":"384","DOI":"10.2165\/00003495-199345030-00007","article-title":"Mifepristone. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential","volume":"45","author":"Brogden","year":"1993","journal-title":"Drugs"},{"key":"10.1053\/beog.2001.0243_RF6","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1056\/NEJM199504133321502","article-title":"Induction of abortion with mifepristone (RU 486) and oral or vaginal misoprostol","volume":"332","author":"el Refaey","year":"1995","journal-title":"New England Journal of Medicine"},{"key":"10.1053\/beog.2001.0243_RF7","doi-asserted-by":"crossref","first-page":"1578","DOI":"10.1016\/0002-9378(95)90652-5","article-title":"A randomised trial comparing misoprostol three and seven days after methotrexate for early abortion","volume":"173","author":"Creinin","year":"1995","journal-title":"American Journal of Obstetrics and Gynecology"},{"key":"10.1053\/beog.2001.0243_RF8","doi-asserted-by":"crossref","first-page":"1881","DOI":"10.1056\/NEJM199806253382604","article-title":"Use of misoprostol during pregnancy and Mobius' syndrome in infants","volume":"338","author":"Pastuszak","year":"1998","journal-title":"New England Journal of Medicine"},{"key":"10.1053\/beog.2001.0243_RF9","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1111\/j.1471-0528.2000.tb13272.x","article-title":"Epidemiological assessment of misoprostol teratogenicity","volume":"107","author":"Orioli","year":"2000","journal-title":"British Journal of Obstetrics and Gynaecology"},{"key":"10.1053\/beog.2001.0243_RF10","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/0140-6736(90)91792-9","article-title":"Normal development after exposure to mifepristone in early pregnancy","volume":"336","author":"Lim","year":"1990","journal-title":"Lancet"},{"key":"10.1053\/beog.2001.0243_RF11","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1111\/j.1471-0528.1997.tb12028.x","article-title":"Medical abortion or vacuum aspiration? Two year follow up of a patient preference trial","volume":"104","author":"Howie","year":"1997","journal-title":"British Journal of Obstetrics and Gynaecology"},{"key":"10.1053\/beog.2001.0243_RF12","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1111\/j.1479-828X.1996.tb02714.x","article-title":"A randomized trial of 2 regimens for the administration of vaginal prostaglandins (gemeprost) for the induction of midtrimester abortion","volume":"36","author":"Armatage","year":"1996","journal-title":"Australian and New Zealand Journal of Obstetrics and Gynaecology"},{"key":"10.1053\/beog.2001.0243_RF13","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/S0010-7824(98)00099-7","article-title":"Vaginal misoprostol compared with vaginal gemeprost in termination of second trimester pregnancy: a randomised trial","volume":"58","author":"Wong","year":"1998","journal-title":"Contraception"},{"key":"10.1053\/beog.2001.0243_RF14","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1111\/j.1471-0528.1988.tb06860.x","article-title":"Beta-mimetics in preterm labour: an overview of the randomised controlled trials","volume":"95","author":"King","year":"1988","journal-title":"British Journal of Obstetrics and Gynaecology"},{"key":"10.1053\/beog.2001.0243_RF15","series-title":"Pregnancy and Childbirth Module, Cochrane Pregnancy and Childbirth Database.","article-title":"Betamimetic tocolysis in preterm labour, Review no 03237","author":"Keirse","year":"1995"},{"key":"10.1053\/beog.2001.0243_RF16","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1016\/S0029-7844(99)00329-4","article-title":"Tocolytics for preterm labour: a systematic review","volume":"94","author":"Gyetvai","year":"1999","journal-title":"Obstetrics and Gynecology"},{"key":"10.1053\/beog.2001.0243_RF17","first-page":"89","article-title":"A systematic review of adverse events documented in the use of currently available treatment of preterm labour","volume":"16","author":"Besinger","year":"1994","journal-title":"Research and Clinical Forums"},{"key":"10.1053\/beog.2001.0243_RF18","series-title":"Pregnancy and Childbirth Module, Cochrane Pregnancy and Childbirth Database.","article-title":"Indomethacin tocolysis in preterm labour","author":"Keirse","year":"1995"},{"key":"10.1053\/beog.2001.0243_RF19","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1016\/S0002-9378(97)70494-0","article-title":"The use of sulindac to prevent cord complications in monoamniotic twins","volume":"176","author":"Peek","year":"1997","journal-title":"American Journal of Obstetrics and Gynecology"},{"key":"10.1053\/beog.2001.0243_RF20","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/S0140-6736(05)62229-5","article-title":"Use of a cyclo-oxygenase type-2-selective non-steroidal anti-inflammatory agent to prevent preterm delivery","volume":"350","author":"Sawdy","year":"1997","journal-title":"Lancet"},{"key":"10.1053\/beog.2001.0243_RF21","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1016\/S0029-7844(97)00182-8","article-title":"Nifedipine and ritodrine in the management of preterm labour: a randomised multicenter trial","volume":"90","author":"Papatsonis","year":"1997","journal-title":"Obstetrics and Gynecology"},{"key":"10.1053\/beog.2001.0243_RF22","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.1016\/S0140-6736(94)92468-6","article-title":"Arrest of preterm labour and prolongation of gestation with glyceryl trinitrate, a nitric oxide donor","volume":"343","author":"Lees","year":"1994","journal-title":"Lancet"},{"key":"10.1053\/beog.2001.0243_RF23","unstructured":"Giles, W, Bisits, A, Jones, I, Kwek, K, The randomised nitric oxide tocolysis trial. Perinatal Society of Australia and New Zealand 5th Annual Congress Proceedings, 2001, 15"},{"key":"10.1053\/beog.2001.0243_RF24","first-page":"133","volume":"108","year":"2001","journal-title":"British Journal of Obstetrics and Gynaecology"},{"key":"10.1053\/beog.2001.0243_RF25","series-title":"The Cochrane Library","article-title":"Antibiotics for preterm labour with intact membranes","author":"King","year":"2001"},{"key":"10.1053\/beog.2001.0243_RF26","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1016\/S0140-6736(95)91868-X","article-title":"Antimicrobial therapy in expectant management of preterm premature of the membranes","volume":"346","author":"Mercer","year":"1995","journal-title":"Lancet"},{"key":"10.1053\/beog.2001.0243_RF27","series-title":"The Cochrane Library","article-title":"Antibiotics for preterm rupture of membranes","author":"Kenyon","year":"2001"},{"key":"10.1053\/beog.2001.0243_RF28","first-page":"E83","article-title":"Scientific rationale for the use of antenatal glucocorticoids to promote fetal development","volume":"1","author":"Ballard","year":"2001","journal-title":"Pediatric Reviews"},{"key":"10.1053\/beog.2001.0243_RF29","series-title":"The Cochrane Library","article-title":"Prophylactic corticosteroids for preterm birth","author":"Crowley","year":"2001"},{"key":"10.1053\/beog.2001.0243_RF30","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/S0002-9378(99)70160-2","article-title":"Repeated antenatal corticosteroids: size at birth and subsequent development","volume":"180","author":"French","year":"1999","journal-title":"American Journal of Obstetrics and Gynecology"},{"key":"10.1053\/beog.2001.0243_RF31","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1016\/S0002-9378(99)70517-X","article-title":"Multiple courses of antenatal corticosteroids and outcome of premature neonates. North American Thyrotropin-Releasing Hormone Study Group","volume":"181","author":"Banks","year":"1999","journal-title":"American Journal of Obstetrics and Gynecology"},{"key":"10.1053\/beog.2001.0243_RF32","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1542\/peds.99.3.311","article-title":"Australian Collaborative Trial of Antenatal Thyrotropin-Releasing Hormone: adverse effects at 12-month follow-up","volume":"99","author":"Crowther","year":"1997","journal-title":"Pediatrics"},{"key":"10.1053\/beog.2001.0243_RF33","series-title":"The Cochrane Library","article-title":"Vaginal misoprostol for cervical ripening and induction of labour","author":"Hofmeyer","year":"2001"},{"key":"10.1053\/beog.2001.0243_RF34","series-title":"The Cochrane Library","article-title":"Mifepristone for the induction of labour","author":"Neilson","year":"2001"},{"key":"10.1053\/beog.2001.0243_RF35","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1097\/00007611-198608000-00010","article-title":"Expectant management of rupture of membranes at term","volume":"79","author":"Morales","year":"1986","journal-title":"Southern Medical Journal"},{"key":"10.1053\/beog.2001.0243_RF36","series-title":"The Cochrane Library","article-title":"Prostaglandins for prelabour rupture of membranes at or near term","author":"Tan","year":"2001"},{"key":"10.1053\/beog.2001.0243_RF37","series-title":"The Cochrane Library","article-title":"Prostaglandins versus oxytocin for prelabour rupture of membranes at or near term","author":"Tan","year":"2001"},{"key":"10.1053\/beog.2001.0243_RF38","series-title":"The Cochrane Library","article-title":"Interventions for preventing or improving the outcome of delivery at or beyond term","author":"Crowley","year":"2001"},{"key":"10.1053\/beog.2001.0243_RF39","series-title":"The Cochrane Library","article-title":"Active versus expectant management in third stage of labour","author":"Prendiville","year":"2001"}],"container-title":["Best Practice & Research Clinical Obstetrics & Gynaecology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521693401902433?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521693401902433?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,4,11]],"date-time":"2019-04-11T20:25:47Z","timestamp":1555014347000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1521693401902433"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2001,12]]},"references-count":39,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2001,12]]}},"alternative-id":["S1521693401902433"],"URL":"https:\/\/doi.org\/10.1053\/beog.2001.0243","relation":{},"ISSN":["1521-6934"],"issn-type":[{"value":"1521-6934","type":"print"}],"subject":[],"published":{"date-parts":[[2001,12]]}}}